Aberrant methylation of PYCARD was detected in a tumor-specific manner in 90% (45/50); these results suggest that the aberrant hypermethylation of PYCARD promoter is frequent in primary prostate carcinomas. Here, PYCARD is linked to prostate carcinoma.